MedTrace Logo

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

NCT00895466 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2009-05-08

No results posted yet for this study

Summary

The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones.

Conditions

Interventions

BIOLOGICAL

PEP-223/CoVaccine HT

Sponsors & Collaborators

  • TFS Trial Form Support

    collaborator INDUSTRY

  • Pepscan Therapeutics

    lead INDUSTRY

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2009-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00895466 on ClinicalTrials.gov